JP2020507567A - 置換グリシン化合物の共結晶およびそれの使用 - Google Patents

置換グリシン化合物の共結晶およびそれの使用 Download PDF

Info

Publication number
JP2020507567A
JP2020507567A JP2019542698A JP2019542698A JP2020507567A JP 2020507567 A JP2020507567 A JP 2020507567A JP 2019542698 A JP2019542698 A JP 2019542698A JP 2019542698 A JP2019542698 A JP 2019542698A JP 2020507567 A JP2020507567 A JP 2020507567A
Authority
JP
Japan
Prior art keywords
crystal
coformer
alkyl
disorder
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019542698A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020507567A5 (enExample
Inventor
エミル ツァイ クオチョアン
エミル ツァイ クオチョアン
チン−チョン ワン
チン−チョン ワン
ティエン−ラン シエ
ティエン−ラン シエ
Original Assignee
シニュークス インターナショナル（タイワン）コーポレイション
シニュークス インターナショナル（タイワン）コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シニュークス インターナショナル（タイワン）コーポレイション, シニュークス インターナショナル（タイワン）コーポレイション filed Critical シニュークス インターナショナル（タイワン）コーポレイション
Publication of JP2020507567A publication Critical patent/JP2020507567A/ja
Publication of JP2020507567A5 publication Critical patent/JP2020507567A5/ja
Priority to JP2023053835A priority Critical patent/JP7723991B2/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/12—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of acyclic carbon skeletons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/235—Saturated compounds containing more than one carboxyl group
    • C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
    • C07C59/255—Tartaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/62—Three oxygen atoms, e.g. ascorbic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
JP2019542698A 2017-02-13 2018-01-11 置換グリシン化合物の共結晶およびそれの使用 Pending JP2020507567A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023053835A JP7723991B2 (ja) 2017-02-13 2023-03-29 置換グリシン化合物の共結晶およびそれの使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/430,750 US9877942B1 (en) 2017-02-13 2017-02-13 Co-crystals of substituted glycine and uses thereof
US15/430,750 2017-02-13
PCT/CN2018/072186 WO2018145553A1 (en) 2017-02-13 2018-01-11 Co-crystals of substituted glycine compounds and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023053835A Division JP7723991B2 (ja) 2017-02-13 2023-03-29 置換グリシン化合物の共結晶およびそれの使用

Publications (2)

Publication Number Publication Date
JP2020507567A true JP2020507567A (ja) 2020-03-12
JP2020507567A5 JP2020507567A5 (enExample) 2021-02-25

Family

ID=61005084

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019542698A Pending JP2020507567A (ja) 2017-02-13 2018-01-11 置換グリシン化合物の共結晶およびそれの使用
JP2023053835A Active JP7723991B2 (ja) 2017-02-13 2023-03-29 置換グリシン化合物の共結晶およびそれの使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023053835A Active JP7723991B2 (ja) 2017-02-13 2023-03-29 置換グリシン化合物の共結晶およびそれの使用

Country Status (11)

Country Link
US (4) US9877942B1 (enExample)
EP (1) EP3579828B1 (enExample)
JP (2) JP2020507567A (enExample)
KR (1) KR20190118574A (enExample)
CN (1) CN110520117A (enExample)
CA (1) CA3051284A1 (enExample)
IL (1) IL268220B (enExample)
MX (1) MX393880B (enExample)
RU (1) RU2019128576A (enExample)
TW (1) TWI670058B (enExample)
WO (1) WO2018145553A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017215593A1 (en) 2016-06-13 2017-12-21 Syneurx International (Taiwan) Corp. Co-crystals of sodium benzoate and uses thereof
US9877942B1 (en) 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof
CN113233976B (zh) * 2021-05-08 2021-11-16 广州萃普生物科技有限公司 一种没食子酸和氨基乙酸共晶及含有该共晶的美白膏霜
JP2024539153A (ja) 2021-10-20 2024-10-28 ピュラック バイオケム ビー． ブイ． クエン酸とグリシンとの共結晶及びその使用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153945A2 (en) * 2007-06-06 2008-12-18 University Of South Florida Nutraceutical co-crystal compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
JP2007516259A (ja) * 2003-12-09 2007-06-21 メッドクリスタルフォームズ、エルエルシー 活性剤との混合相共結晶の調製方法
WO2009018368A1 (en) * 2007-07-30 2009-02-05 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Combination treatment of nmda (n-methyl-d-aspartate)-enhancer, glycine transporter inhibitor, d-amino acid oxidase inhibitor (daaoi) for neuropsychiatric disorders
GB201411802D0 (en) * 2014-07-02 2014-08-13 Univ Bradford Effervescent compositions
US9877942B1 (en) 2017-02-13 2018-01-30 Syneurx International (Taiwan) Corp. Co-crystals of substituted glycine and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008153945A2 (en) * 2007-06-06 2008-12-18 University Of South Florida Nutraceutical co-crystal compositions

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ＡＣＴＡ ＣＲＹＳＴＡＬＬＯＧＲＡＰＨＩＣＡ ＳＥＣＴＩＯＮ Ｃ, vol. 57, JPN6022003126, 2001, pages 165 - 166, ISSN: 0004931521 *
ＢＲＡＩＮ ＲＥＳＥＡＲＣＨ ＢＵＬＬＥＴＩＮ, vol. 69, no. 6, JPN6022003129, 30 March 2006 (2006-03-30), pages 626 - 630, ISSN: 0004931523 *
ＪＯＵＲＮＡＬ ＯＦ ＭＯＬＥＣＵＬＡＲ ＳＴＲＵＣＴＵＲＥ, vol. 1045, JPN6022003125, 6 August 2013 (2013-08-06), pages 95 - 103, ISSN: 0004931519 *
ＪＯＵＲＮＡＬ ＯＦ ＰＨＹＳＩＣＡＬ ＣＨＥＭＩＳＴＲＹ Ａ, vol. 119, no. 49, JPN6022003131, 12 November 2015 (2015-11-12), pages 11891 - 11899, ISSN: 0004931520 *
ＳＰＥＣＴＲＯＣＨＩＭＩＣＡ ＡＣＴＡ ＰＡＲＴ Ａ, vol. 59, no. 8, JPN6022003128, 2003, pages 1815 - 1828, ISSN: 0004931522 *

Also Published As

Publication number Publication date
EP3579828A1 (en) 2019-12-18
US10328042B2 (en) 2019-06-25
EP3579828B1 (en) 2025-03-26
IL268220A (en) 2019-09-26
US10328041B2 (en) 2019-06-25
CN110520117A (zh) 2019-11-29
TWI670058B (zh) 2019-09-01
JP2023082101A (ja) 2023-06-13
MX2019009616A (es) 2019-10-14
US9877942B1 (en) 2018-01-30
US10765651B2 (en) 2020-09-08
US20180228754A1 (en) 2018-08-16
US20180228753A1 (en) 2018-08-16
US20190262299A1 (en) 2019-08-29
TW201840308A (zh) 2018-11-16
KR20190118574A (ko) 2019-10-18
IL268220B (en) 2022-04-01
WO2018145553A1 (en) 2018-08-16
MX393880B (es) 2025-03-24
JP7723991B2 (ja) 2025-08-15
CA3051284A1 (en) 2018-08-16
RU2019128576A (ru) 2021-03-15
RU2019128576A3 (enExample) 2021-05-14
EP3579828A4 (en) 2020-11-18

Similar Documents

Publication Publication Date Title
JP7723991B2 (ja) 置換グリシン化合物の共結晶およびそれの使用
US11731928B2 (en) Co-crystals of sodium benzoate and uses thereof
US11739046B2 (en) Co-crystals of lithium benzoate and uses thereof
RU2771810C2 (ru) Сокристаллы бензоата натрия и их применение
HK40017282A (en) Co-crystals of substituted glycine compounds and uses thereof
HK40017282B (en) Co-crystals of substituted glycine compounds and uses thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210112

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220201

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220801

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221129